Angioimmunoblastic Lymphadenopathy with Dysproteinemia. A Pathogenetic Link Between Lymphoid Proliferation and Malignant Lymphoma
Overview
Authors
Affiliations
Two patients with angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) were studied. Both patients had marked increases in all three major immunoglobulin classes, and both lacked suppressor cell activity in vitro. These findings are consistent with the theory that AILD is a defectively regulated immune response to an unidentified antigen(s) and could provide clues to the pathogenesis of other lymphoproliferative disorders as well.
Au W, Liang R Curr Oncol Rep. 2002; 4(5):434-42.
PMID: 12162919 DOI: 10.1007/s11912-002-0038-7.
PLATZER E, Von Roemeling R, Kaduk B, Meinl U Klin Wochenschr. 1981; 59(10):509-16.
PMID: 7241951 DOI: 10.1007/BF01696213.
Lymphoproliferations in the bone marrow: identification and evolution, classification and staging.
Bartl R, Frisch B, Burkhardt R, Jager K, Pappenberger R, Hoffmann-Fezer G J Clin Pathol. 1984; 37(3):233-54.
PMID: 6699189 PMC: 498694. DOI: 10.1136/jcp.37.3.233.
Knecht H, Schwarze E, Lennert K Virchows Arch A Pathol Anat Histopathol. 1985; 406(1):105-24.
PMID: 3922106 DOI: 10.1007/BF00710561.
Evidence for monoclonal T lymphocyte proliferation in angioimmunoblastic lymphadenopathy.
OConnor N, Crick J, Wainscoat J, Gatter K, STEIN H, Falini B J Clin Pathol. 1986; 39(11):1229-32.
PMID: 3491840 PMC: 1140768. DOI: 10.1136/jcp.39.11.1229.